Vinflunine ditartrate 酒石酸长春氟宁|cas:194468-36-5|西域试剂

Vinflunine ditartrate 酒石酸长春氟宁

产品编号：Bellancom-B0628B| CAS NO：194468-36-5| 分子式：C₅₃H₆₆F₂N₄O₂₀| 分子量：1117.10

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-B0628B		￥4000.00	杭州北京（现货）
Bellancom-B0628B		￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Vinflunine ditartrate 酒石酸长春氟宁

产品介绍

Vinflunine ditartrate 是一种长春花生物碱家族的氟化微管抑制剂。Vinflunine ditartrate 具有抗血管生成，破坏血管和抗转移的活性。Vinflunine ditartrate 可用于尿路上皮移行细胞癌，非小细胞肺癌和乳腺癌的研究。

生物活性

Vinflunine ditartrate is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine ditartrate has anti-angiogenic, vascular-disrupting and anti-metastatic activities. Vinflunine ditartrate can be used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast.

体外研究

Vinflunine (0.01-10 μM; 45 min) induces a rapid change in endothelial cell shape: cells retracted and assumed a rounded morphology.
Vinflunine (0.01-10 μM; 1 h) disrupts newly formed capillary-like structures.
Vinflunine (0.01-10 μM; 1 h) inhibits endothelial cell motility, with an IC₅₀ of 0.71 μM.
Vinflunine (0.001-10 μM; 1-72 h) inhibits endothelial cell proliferation in vitro.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Vinflunine (0.08-20 mg/kg; i.v.) reduces the number of experimental liver metastases by human LS174T colon cancer cells.
Vinflunine (0.63-5 mg/kg; i.v. before and 2 d after Matrigel implantation) inhibits the bFGF-induced angiogenic response in mice in a dose-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice (BALB/c/Ola/Hsd-nu) were implanted LS174T cells
Dosage:	0.08, 0.16, 1.25, 5, 10, 20 mg/kg
Administration:	I.v. on days 4, 7, 11, 14, 18 and 21 after tumour cell implantation
Result:	Induced a dose-dependent reduction in the number of metastatic foci at the surface of the liver and was well tolerated.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice (BALB/c/Ola/Hsd-nu) were implanted LS174T cells
Dosage:	0.08, 0.16, 1.25, 5, 10, 20 mg/kg
Administration:	I.v. on days 4, 7, 11, 14, 18 and 21 after tumour cell implantation
Result:	Induced a dose-dependent reduction in the number of metastatic foci at the surface of the liver and was well tolerated.